The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer | PLOS ONE
![Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment | British Journal of Cancer Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fbjc.2016.372/MediaObjects/41416_2016_Article_BFbjc2016372_Fig1_HTML.jpg)
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment | British Journal of Cancer
![Understanding resistance to EGFR inhibitors—impact on future treatment strategies | Nature Reviews Clinical Oncology Understanding resistance to EGFR inhibitors—impact on future treatment strategies | Nature Reviews Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fnrclinonc.2010.97/MediaObjects/41571_2010_Article_BFnrclinonc201097_Fig1_HTML.jpg)
Understanding resistance to EGFR inhibitors—impact on future treatment strategies | Nature Reviews Clinical Oncology
![Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations* - Journal of Biological Chemistry Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations* - Journal of Biological Chemistry](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/6ebd6434-b2d0-4304-85b7-2e99d2acc5f2/gr1_lrg.jpg)
Epidermal Growth Factor Receptor (EGFR) Antibody Down-regulates Mutant Receptors and Inhibits Tumors Expressing EGFR Mutations* - Journal of Biological Chemistry
![Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response - ScienceDirect Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0160412021006140-ga1.jpg)
Unraveling the differential impact of PAHs and dioxin-like compounds on AKR1C3 reveals the EGFR extracellular domain as a critical determinant of the AHR response - ScienceDirect
![EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S037851732031067X-gr1.jpg)
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect
![Neuregulin 1–activated ERBB4 as a “dedicated” receptor for the Hippo-YAP pathway | Science Signaling Neuregulin 1–activated ERBB4 as a “dedicated” receptor for the Hippo-YAP pathway | Science Signaling](https://www.science.org/cms/asset/da97e222-7d7f-4ecf-9861-d299ef73c758/7355pe29_f1.gif)
Neuregulin 1–activated ERBB4 as a “dedicated” receptor for the Hippo-YAP pathway | Science Signaling
![Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries | Molecular Pharmacology Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries | Molecular Pharmacology](https://molpharm.aspetjournals.org/content/molpharm/98/1/13/F4.large.jpg)
Inhibition of Brain Epidermal Growth Factor Receptor Activation: A Novel Target in Neurodegenerative Diseases and Brain Injuries | Molecular Pharmacology
![Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients | British Journal of Cancer Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients | British Journal of Cancer](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fsj.bjc.6604781/MediaObjects/41416_2009_Article_BF6604781_Fig1_HTML.jpg)
Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients | British Journal of Cancer
![Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation | EMBO reports Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation | EMBO reports](https://www.embopress.org/cms/asset/ca530dcf-c177-4573-bfa4-e392469ba2d7/embr201744767-abs-0001-m.jpg)
Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation | EMBO reports
![EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S037851732031067X-ga1.jpg)
EGFR targeting for cancer therapy: Pharmacology and immunoconjugates with drugs and nanoparticles - ScienceDirect
![Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer | Experimental & Molecular Medicine Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer | Experimental & Molecular Medicine](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs12276-018-0202-2/MediaObjects/12276_2018_202_Fig1_HTML.png)
Beyond EGFR inhibition: multilateral combat strategies to stop the progression of head and neck cancer | Experimental & Molecular Medicine
![Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies | Oncogene Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies | Oncogene](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41388-017-0045-7/MediaObjects/41388_2017_45_Fig1_HTML.jpg)
Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies | Oncogene
![Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer | SpringerLink Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs11523-017-0479-4/MediaObjects/11523_2017_479_Fig1_HTML.gif)
Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer | SpringerLink
![The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer](https://www.spandidos-publications.com/article_images/or/44/1/OR-44-01-0185-g06.jpg)
The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer
![Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy | Cell Communication and Signaling | Full Text Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy | Cell Communication and Signaling | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12964-022-00960-x/MediaObjects/12964_2022_960_Fig1_HTML.png)
Promotion or remission: a role of noncoding RNAs in colorectal cancer resistance to anti-EGFR therapy | Cell Communication and Signaling | Full Text
![Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer - Annals of Oncology Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/f0214453-e564-4fc3-8410-3d6ca9f7c9f0/gr1.jpg)
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer - Annals of Oncology
![Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations | Science Signaling Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations | Science Signaling](https://www.science.org/cms/asset/fa11c024-ab23-4d49-8e9d-f2601b6d019f/7_ra114_f1.gif)
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations | Science Signaling
![Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies | Nature Communications Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies | Nature Communications](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41467-018-06602-6/MediaObjects/41467_2018_6602_Fig1_HTML.png)
Improvement and extension of anti-EGFR targeting in breast cancer therapy by integration with the Avidin-Nucleic-Acid-Nano-Assemblies | Nature Communications
![The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered - Gan - 2013 - The FEBS Journal - Wiley Online Library The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered - Gan - 2013 - The FEBS Journal - Wiley Online Library](https://febs.onlinelibrary.wiley.com/cms/asset/1e00f02c-06a6-4154-a238-5309aeef3ec2/febs12393-fig-0001-m.jpg)